Revance Therapeutics, Inc.
Biotechnology ResearchUnited States501-1000 Employees
We are pleased to announce that Crown Laboratories and Revance Therapeutics are now united as REVANCE.
Innovative Product Launches Revance has recently launched new aesthetic and skincare products such as the Teoxane RHA Collection and the PanOxyl Acne Gel Wash, indicating ongoing product development that could benefit from advanced sales enablement tools and customer engagement platforms.
Expansion in Aesthetic Market With its focus on aesthetics and skincare, Revance is positioned in a high-growth segment that is increasingly driven by technological innovation, offering opportunities for partnerships in marketing automation, CRM integration, and data analytics to boost customer reach.
Strategic Leadership Appointments Recent high-level hires including a new CEO and CFO suggest a strategic focus on scaled growth and market expansion, creating potential for upselling enterprise-grade technologies and compliance solutions to support corporate governance.
Financial Growth Potential Revance reports substantial revenue between 250M and 500M dollars with recent funding of 100M, indicating financial stability and growth prospects that could be leveraged for offering scalable SaaS solutions, enterprise software, and consulting services.
Market Position & Competitors As a key player among competitors like Merz Aesthetics and Galderma, Revance's market position presents opportunities for tailored marketing, competitive intelligence tools, and customer relationship management solutions to enhance their market share and customer loyalty.
Revance Therapeutics, Inc. uses 8 technology products and services including Tableau, Salesforce, Font Awesome, and more. Explore Revance Therapeutics, Inc.'s tech stack below.
| Revance Therapeutics, Inc. Email Formats | Percentage |
| First.Last@revance.com | 55% |
| FLast@revance.com | 38% |
| FirstLast@revance.com | 5% |
| Last@revance.com | 2% |
Biotechnology ResearchUnited States501-1000 Employees
We are pleased to announce that Crown Laboratories and Revance Therapeutics are now united as REVANCE.
Revance Therapeutics, Inc. has raised a total of $100M of funding over 17 rounds. Their latest funding round was raised on Mar 04, 2024 in the amount of $100M.
Revance Therapeutics, Inc.'s revenue is estimated to be in the range of $250M$500M
Revance Therapeutics, Inc. has raised a total of $100M of funding over 17 rounds. Their latest funding round was raised on Mar 04, 2024 in the amount of $100M.
Revance Therapeutics, Inc.'s revenue is estimated to be in the range of $250M$500M